A Phase 2 Study of Neoadjuvant Vemurafenib in Melanoma Patients With Untreated Brain Metastases, Whose Tumors Harbor B-raf Mutations

Trial Profile

A Phase 2 Study of Neoadjuvant Vemurafenib in Melanoma Patients With Untreated Brain Metastases, Whose Tumors Harbor B-raf Mutations

Completed
Phase of Trial: Phase II

Latest Information Update: 15 Mar 2017

At a glance

  • Drugs Vemurafenib (Primary)
  • Indications Brain metastases; Malignant melanoma
  • Focus Therapeutic Use
  • Most Recent Events

    • 01 Apr 2015 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
    • 01 Apr 2013 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov.
    • 29 Jan 2013 New source identified: ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top